Rizatriptan Glenmark: Uses, Dosage & Side Effects

What Is Rizatriptan Glenmark and What Is It Used For?

Rizatriptan Glenmark belongs to the pharmacological class of selective serotonin 5-HT1B/1D receptor agonists, commonly referred to as triptans. Triptans are the most widely prescribed class of medications specifically developed for the acute treatment of migraine attacks, and rizatriptan is recognized by the World Health Organization (WHO), the European Medicines Agency (EMA), and the American Headache Society (AHS) as a first-line option for moderate-to-severe migraine headaches that do not respond adequately to simple analgesics or non-steroidal anti-inflammatory drugs (NSAIDs).

The mechanism of action of rizatriptan is multi-faceted and targets the pathophysiology of migraine at several key points. During a migraine attack, trigeminal sensory nerve fibers release vasoactive neuropeptides – most notably calcitonin gene-related peptide (CGRP), substance P, and neurokinin A – into the perivascular space surrounding intracranial blood vessels. This release triggers neurogenic inflammation, vasodilation, and sensitization of pain-processing pathways in the brainstem. Rizatriptan acts by binding with high affinity to serotonin 5-HT1B receptors on intracranial blood vessels, causing vasoconstriction and reducing the perivascular swelling that produces throbbing migraine pain. Simultaneously, rizatriptan activates 5-HT1D receptors on trigeminal nerve terminals, inhibiting the release of pro-inflammatory neuropeptides and dampening pain signal transmission through the trigeminal pathway to the thalamus and cortex.

Clinical studies have established rizatriptan as one of the most effective and fastest-acting triptans currently available. In landmark randomized controlled trials (including the pivotal studies by Visser et al. and Tfelt-Hansen et al.), the 10 mg dose of rizatriptan demonstrated superior 2-hour pain-free rates compared with sumatriptan 100 mg, the most commonly used triptan worldwide. Approximately 67–77% of patients experience meaningful headache relief within 2 hours of taking rizatriptan 10 mg, and 40–47% achieve complete pain freedom at 2 hours. Importantly, onset of relief can begin as early as 30 minutes, making rizatriptan particularly valuable for patients who require rapid resolution of their migraine symptoms.

Rizatriptan Glenmark is formulated as an orodispersible tablet (also known as an orally disintegrating tablet, ODT), which represents a significant practical advantage over conventional tablet formulations. The orodispersible tablet is designed to be placed on the tongue, where it rapidly disintegrates and can be swallowed with saliva without the need for water. This delivery system is especially beneficial during migraine attacks when patients frequently experience nausea, vomiting, and gastroparesis (delayed stomach emptying), which can make swallowing conventional tablets with liquid difficult or impractical. The orodispersible formulation provides comparable bioavailability to standard oral tablets, with peak plasma concentrations reached within approximately 1 to 1.5 hours.

It is critically important to understand that Rizatriptan Glenmark is indicated exclusively for the acute treatment of migraine headache attacks. It should not be used to prevent or reduce the frequency of migraine episodes. Additionally, rizatriptan is effective only against migraine headache and should not be taken for tension-type headache or other non-migraine headache conditions. If you are unsure whether your headaches are migraine, consult your doctor for a proper diagnosis before using this medication.

What Should You Know Before Taking Rizatriptan Glenmark?

Contraindications

There are several absolute contraindications to the use of Rizatriptan Glenmark. You must not take this medication if any of the following apply to you:

• Allergy: Hypersensitivity to rizatriptan benzoate or any of the other ingredients in the formulation (listed in the Contents section below).
• Hypertension: Moderate or severe high blood pressure, or mild hypertension that is not adequately controlled with medication. Triptans cause vasoconstriction, which can further increase blood pressure to dangerous levels.
• Cardiovascular disease: A history of coronary artery disease, including previous myocardial infarction (heart attack), angina pectoris (chest pain), documented or suspected ischemic heart disease, or symptoms suggestive of heart disease. Rizatriptan constricts coronary arteries and may precipitate coronary vasospasm.
• Cerebrovascular disease: History of stroke (cerebrovascular accident) or transient ischemic attack (TIA, “mini-stroke”).
• Peripheral vascular disease: Reduced blood flow to the arms or legs caused by arterial blockage.
• Severe hepatic or renal impairment: Patients with severe liver or kidney dysfunction should not use rizatriptan, as drug clearance is significantly reduced.
• Concomitant MAO inhibitors: Do not use rizatriptan if you are taking monoamine oxidase (MAO) inhibitors such as moclobemide, phenelzine, tranylcypromine, pargyline, or the antibiotic linezolid, or if fewer than two weeks have passed since discontinuation of an MAO inhibitor. MAO-A is the primary metabolic pathway for rizatriptan, and inhibition of this enzyme dramatically increases rizatriptan exposure.
• Concomitant ergotamines: Do not use rizatriptan with ergotamine, dihydroergotamine, or methysergide due to the risk of additive vasoconstriction and potentially life-threatening vasospasm.
• Concomitant other triptans: Do not combine rizatriptan with any other 5-HT1B/1D agonist (such as sumatriptan, naratriptan, or zolmitriptan) for the same reason.

Warnings and Precautions

Discuss the following conditions with your doctor before taking Rizatriptan Glenmark:

• Cardiovascular risk factors: If you have risk factors for coronary artery disease (high blood pressure, diabetes, smoking or nicotine replacement use, family history of heart disease, male over 40 years, post-menopausal female), your doctor may recommend a cardiovascular assessment before prescribing rizatriptan.
• Mild hepatic or renal impairment: If you have mild-to-moderate liver or kidney problems, your doctor may recommend the 5 mg dose and limit the maximum to two doses per 24 hours.
• Cardiac conduction disorders: If you have a specific type of heart rhythm problem known as bundle branch block, inform your doctor.
• Allergic history: If you have a history of allergic reactions, particularly angioedema (swelling of the face, lips, tongue, or throat), discuss this with your doctor.
• Atypical headache: If your headache is accompanied by dizziness, difficulty walking, coordination problems, or weakness in the arms or legs, these symptoms may indicate a serious neurological condition rather than migraine. Seek medical attention before taking rizatriptan.
• Medication overuse headache: Using rizatriptan too frequently can paradoxically lead to chronic daily headache (medication overuse headache, MOH). If you find yourself needing to take rizatriptan more than 10 days per month, contact your doctor, as you may need to stop the medication and pursue alternative treatment strategies.

Pregnancy and Breastfeeding

If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Rizatriptan Glenmark. Available data on rizatriptan use during the first trimester of pregnancy have not demonstrated an increased risk of congenital malformations. However, the safety of rizatriptan when taken after the first three months of pregnancy has not been established. As a precaution, rizatriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Rizatriptan may pass into breast milk. To avoid exposing your infant to the medication, you should refrain from breastfeeding for 12 hours after taking Rizatriptan Glenmark. Express and discard any breast milk produced during this 12-hour window.

Driving and Operating Machinery

Rizatriptan may cause drowsiness or dizziness in some patients. Both the migraine attack itself and the medication can impair your ability to drive or operate machinery safely. If you experience drowsiness, dizziness, or any other side effects that affect your alertness after taking Rizatriptan Glenmark, do not drive or operate machinery until these effects have completely resolved. You are personally responsible for assessing whether you are fit to drive or perform tasks that require alertness.

Important Information About Ingredients

Rizatriptan Glenmark orodispersible tablets contain aspartam (E951), which is a source of phenylalanine. The 5 mg tablet contains 4 mg of aspartam, and the 10 mg tablet contains 8 mg of aspartam. Aspartam may be harmful to individuals with phenylketonuria (PKU), a rare inherited metabolic disorder that leads to accumulation of high levels of phenylalanine in the body. If you have PKU, inform your doctor before taking this medication.

How Does Rizatriptan Glenmark Interact with Other Drugs?

Unlike some newer migraine therapies, rizatriptan has a number of clinically important drug interactions that both patients and prescribers must be aware of. Rizatriptan is primarily metabolized by monoamine oxidase type A (MAO-A), and its pharmacokinetics can be significantly affected by drugs that inhibit this enzyme. Additionally, combining rizatriptan with other vasoconstrictive or serotonergic medications can increase the risk of serious adverse events.

Major Interactions (Contraindicated)

The following drug combinations are absolutely contraindicated with Rizatriptan Glenmark and must never be used together:

Moderate Interactions (Dose Adjustment or Monitoring Required)

Importantly, other commonly used beta-blockers (such as metoprolol, atenolol, and nadolol) do not appear to significantly affect rizatriptan pharmacokinetics and do not require dose adjustment. The interaction is specific to propranolol because it inhibits MAO-A activity, which is the primary metabolic pathway for rizatriptan.

If you are taking an SSRI (such as sertraline, escitalopram, or fluoxetine) or an SNRI (such as venlafaxine or duloxetine) for depression or anxiety, you should be aware of the theoretical risk of serotonin syndrome when combined with rizatriptan. Serotonin syndrome is a rare but potentially life-threatening condition caused by excessive serotonergic activity in the central nervous system. Symptoms include agitation, confusion, hallucinations, rapid heart rate, fluctuating blood pressure, elevated body temperature, lack of coordination, muscle twitching, nausea, vomiting, and diarrhea. If you develop these symptoms after taking rizatriptan with an SSRI or SNRI, seek immediate medical attention.

What Is the Correct Dosage of Rizatriptan Glenmark?

Adults (18–65 years)

The recommended dose of Rizatriptan Glenmark for adults is 10 mg, taken as soon as possible after the onset of migraine headache. Take the orodispersible tablet from the blister pack with dry hands and place it on your tongue. The tablet will dissolve rapidly and can be swallowed with your saliva – no water or other liquid is needed. This makes the orodispersible formulation particularly useful in situations where drinks are not available, or when nausea and vomiting accompanying the migraine make it difficult to swallow conventional tablets.

Rizatriptan should be taken early in the migraine attack for optimal results. Clinical evidence shows that early treatment, when pain is still mild-to-moderate, is associated with higher rates of complete pain freedom and reduced recurrence compared with delayed treatment. However, rizatriptan is effective at all stages of the headache phase, so it can still provide benefit even when taken after the migraine has progressed to severe intensity.

Migraine Recurrence Within 24 Hours

In some patients, migraine symptoms may return after initial relief. This is known as migraine recurrence and occurs in approximately 20–40% of patients treated with any triptan. If your migraine returns within 24 hours of the first dose, you may take a second dose of Rizatriptan Glenmark, provided that at least 2 hours have passed since the first dose. Do not take more than two doses of the same strength within a 24-hour period (i.e., maximum 2 × 10 mg or 2 × 5 mg).

If the First Dose Does Not Work

If your migraine headache does not improve within 2 hours of taking the first dose of Rizatriptan Glenmark, do not take a second dose for the same attack. A second dose for the same unresponsive attack has not been shown to provide additional benefit and is not recommended. However, rizatriptan is likely to be effective in your next migraine attack, so you should still use it when your next migraine occurs. If you consistently find that rizatriptan does not relieve your migraines, consult your doctor to discuss alternative treatment options.

Children and Adolescents

Rizatriptan Glenmark is not recommended for use in children and adolescents under 18 years of age. There is insufficient clinical experience with rizatriptan in this age group, and the safety and efficacy have not been established in pediatric patients. Migraine in children and adolescents may require different treatment approaches, and age-appropriate alternatives should be discussed with a pediatric neurologist or headache specialist.

Elderly Patients (Over 65 Years)

There are no adequate and well-controlled studies evaluating the safety and efficacy of Rizatriptan Glenmark in patients over 65 years of age. Given the increased prevalence of cardiovascular disease in this population, and the vasoconstrictive properties of triptans, rizatriptan should be used with particular caution in elderly patients, if at all. Your doctor will assess whether the benefits outweigh the risks in your individual case.

Overdose

If you or someone else has taken too much Rizatriptan Glenmark, or if a child has accidentally ingested the medication, contact your doctor, hospital emergency department, or poison control center immediately for assessment and advice. Symptoms of overdose may include dizziness, drowsiness, vomiting, fainting, and slow heart rate (bradycardia). There is no specific antidote for rizatriptan overdose; treatment is supportive and symptomatic.

What Are the Side Effects of Rizatriptan Glenmark?

Like all medicines, Rizatriptan Glenmark can cause side effects, although not everybody will experience them. In clinical studies involving adults, the most frequently reported adverse effects were dizziness, drowsiness, and fatigue. The following side effects have been reported with rizatriptan, organized by their frequency of occurrence:

The majority of side effects associated with rizatriptan are mild to moderate in intensity and resolve spontaneously within a few hours. The most commonly reported effects – dizziness, drowsiness, and fatigue – are consistent with the known pharmacology of triptans and may also overlap with symptoms of the migraine attack itself. In clinical trials, the discontinuation rate due to adverse events was low and comparable to placebo, indicating that rizatriptan is generally well tolerated.

Chest pain and a sensation of tightness in the chest, throat, or jaw (“triptan sensations”) have been reported with rizatriptan and other triptans. In most cases, these sensations are not cardiac in origin and are thought to result from smooth muscle constriction in the esophagus or skeletal muscle. However, because triptans can cause coronary vasospasm, any chest pain occurring after rizatriptan use should be evaluated promptly by a healthcare provider to rule out a cardiac cause, particularly in patients with cardiovascular risk factors.

Long-term use of rizatriptan or any triptan on more than 10 days per month can lead to medication overuse headache (MOH), also known as rebound headache. In this condition, the frequency and severity of headaches paradoxically increase with ongoing triptan use. If you suspect you may be developing medication overuse headache, consult your doctor. The treatment typically involves gradual withdrawal of the overused medication under medical supervision.

How Should You Store Rizatriptan Glenmark?

Rizatriptan Glenmark orodispersible tablets do not require any special storage conditions. Store the tablets in their original aluminum/aluminum blister packaging at room temperature. There is no need for refrigeration or protection from light, though it is advisable to keep the tablets in a cool, dry place away from excessive heat or humidity.

Keep Rizatriptan Glenmark out of the sight and reach of children at all times. Accidental ingestion by a child may cause serious symptoms, and you should contact your doctor or poison control center immediately if this occurs.

Do not use Rizatriptan Glenmark after the expiration date printed on the packaging after “EXP.” The expiration date refers to the last day of the stated month. Using expired medication may result in reduced efficacy and is not recommended.

Do not dispose of medications by flushing them down the drain or throwing them in household waste. Return any unused or expired tablets to your pharmacist for proper disposal. These measures help protect the environment from pharmaceutical contamination of waterways and soil.

What Does Rizatriptan Glenmark Contain?

Active Ingredient

The active substance is rizatriptan, present as rizatriptan benzoate. Each 5 mg orodispersible tablet contains 5 mg of rizatriptan, equivalent to 7.265 mg of rizatriptan benzoate. Each 10 mg orodispersible tablet contains 10 mg of rizatriptan, equivalent to 14.53 mg of rizatriptan benzoate. Rizatriptan benzoate is the salt form of the active molecule that provides optimal stability and bioavailability in the orodispersible tablet formulation.

Inactive Ingredients (Excipients)

Appearance and Pack Sizes

The 5 mg orodispersible tablets are white to off-white, round, flat with beveled edges, imprinted with “467” on one side and plain on the other side. The 10 mg orodispersible tablets are white to off-white, round, flat with beveled edges, imprinted with “468” on one side and plain on the other side. Both strengths are packaged in aluminum/aluminum blister packs.

The 5 mg strength is available in packs of 3, 6, or 18 orodispersible tablets. The 10 mg strength is available in packs of 2, 3, 6, 12, or 18 orodispersible tablets. Not all pack sizes may be marketed in every country. Rizatriptan benzoate is also available as conventional tablets intended to be swallowed with liquid.

Marketing Authorization Holder and Manufacturer

The marketing authorization holder is Glenmark Arzneimittel GmbH (Industriestr. 31, 82194 Gröbenzell, Germany). Manufacturing is performed by Glenmark Pharmaceuticals Europe Limited (Croxley Green Business Park, Hertfordshire, United Kingdom) and Glenmark Pharmaceuticals s.r.o. (Fibichova 143, 566 17 Vysoké Mýto, Czech Republic). Rizatriptan Glenmark is approved and marketed in multiple European Economic Area (EEA) countries under various local trade names.